Longevity

A March 2025 NEJM trial reported that a single lepodisiran injection cut lipoprotein(a) by about 94 percent for most of a year. With pelacarsen outcomes now expected in early 2026, Lp(a) is shifting from genetic liability to actionable target.

The FDA’s September 2025 pivot on LDT oversight is sending epigenetic and proteomic aging clocks back into hospitals. Here is what returns, where these tests fit first, and the validation guardrails that make them clinical tools.

In 2025, Klotho moved from lab curiosity to clinical contender. A lifespan-extending mouse study and XPRIZE Healthspan’s coordinated trial framework now position tunable mRNA to reach first-in-human testing as early as 2026.

A quiet milestone on February 26, 2025 signaled a loud shift in medicine. With FDA acceptance of a lifespan claim for a dog drug and the Dog Aging Project’s rapamycin trial expanding, companion animals are opening a faster path to human gerotherapies.

In 2025, gene-edited pig kidneys and livers supported function in living patients. On January 25, 2025, Mass General implanted a second gene-edited pig kidney into a living recipient. On October 9, 2025, a peer-reviewed case reported an auxiliary pig liver sustaining function for 38 days. Organ failure is turning into an engineering problem.

Unity Biotechnology’s senolytic UBX1325 kept pace with aflibercept over 36 weeks in diabetic macular edema, with clean ocular safety and a clear responder subgroup. Here is why the eye was the right proving ground and what this means for the next wave of aging drugs.

A June 2025 study reframes CAR T engineering by showing these living drugs can become senescent. Here is the practical playbook to prevent aging in therapeutic cells and to turn the same insights into senolytic immunotherapy for real-world diseases.

Late‑August 2025 data show that low‑dose colchicine slows the growth of TET2‑driven clonal hematopoiesis in coronary disease. This could be the first genomically tracked aging process clinicians can modify, with a practical playbook for testing, treatment, and trials.

A randomized Aging Cell readout showing 1 to 3 year shifts in biological age has pushed therapeutic plasma exchange from fringe idea to testable program. Here is what the data show, what they do not, and a blueprint to move fast without overselling.

A 2025 randomized-trial analysis reports semaglutide nudged several DNA methylation clocks toward a younger profile. Here is what that does and does not prove, and how to translate a weight-loss wave into real healthspan gains.

In April 2025, the FDA put VERVE-102 on Fast Track and early Heart-2 results showed deep LDL reductions after a single infusion. Here is what PCSK9 base editing could mean for prevention, safety, durability, and the road to Phase 2.

A quiet organ in your chest is emerging as the master switch of immune aging. In 2025, new metabolism data, iPSC thymus breakthroughs, and fresh U.S. funding outline a clinic-ready plan to reset immune age.

A standardized, tissue specific multi-omics map of senescent cell states puts validated biomarkers into the hands of researchers. The result is a clear path to precision diagnostics, smarter trials, and the next wave of senotherapeutics.

A wave of 2025 OSK data in primates and metabolic models is pulling partial epigenetic reprogramming toward the clinic. Learn why ophthalmology leads, how control systems make it feasible, and what to watch next.

In February 2025, the FDA accepted preliminary efficacy (RXE) for a senior-dog longevity pill and expanded conditional approval rules now give it a path to market. Together they create the first large, real-world testbed for geroprotectors and may shorten the road to human aging therapies.

In June 2025, Vertex’s stem cell islet therapy zimislecel posted Phase 1/2 results with A1c under 7 percent and insulin independence for most at one year, pivoting the field from devices toward immunosuppression-first strategies.

A first wave of peer-reviewed and conference data tests senescent cell clearance in the clinic. UBX1325’s 2025 diabetic macular edema results point to durable, disease-modifying vision gains and a credible path to Phase 3.

A Financial Times scoop on LinkGevity’s necrosis‑blocking combo just put regulated necrosis on the geroscience map. Here is why stopping injury‑triggered cell death could cool inflammaging, where first wins may arrive, and how to measure them fast.